A non-inferiority, phase III trial of gemcitabine plus capecitabine <i>versus</i> gemcitabine plus carboplatin as first-line therapy and tumor-infiltrating lymphocytes as a prognostic biomarker in patients with advanced triple-negative breast cancer
Xiaodong Liu(Tianjin Medical University Cancer Institute and Hospital), Zhongsheng Tong(Institute of Oncology NN Petrov), Yehui Shi(Tianjin Medical University Cancer Institute and Hospital), Chunfang Hao(Tianjin Medical University Cancer Institute and Hospital), Weipeng Zhao(Tianjin Medical University Cancer Institute and Hospital), Yongsheng Jia(Tianjin Medical University Cancer Institute and Hospital), Chen Wang(Kunming University of Science and Technology), Xu Wang(Shanghai Medical College of Fudan University), Pin Zhang(Peking University), Shufen Li(Tianjin University)
Cited by 2
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Nuclear mass table in deformed relativistic Hartree–Bogoliubov theory in continuum, I: Even–even nuclei
|Atomic Data and Nuclear Data Tables|2022|175
Study on preparation of Ca/Al/Fe3O4 magnetic composite solid catalyst and its application in biodiesel transesterification
|Fuel Processing Technology|2011|154
Transesterification of Rapeseed Oil for Synthesizing Biodiesel by K/KOH/γ‐Al<sub>2</sub>O<sub>3</sub> as Heterogeneous Base Catalyst
|Journal of the American Oil Chemists Society|2008|117